Doyle Raizner Pradaxa Case Chosen for Bellwether Early Trial Consideration
(PRWEB) July 30, 2013 -- As progress continues in the Pradaxa multi district litigation (MDL), the bellwether case selection process has concluded with one of Doyle Raizner’s cases being chosen. Doyle Raizner’s case is one of 16 cases out of approximately 871 currently pending cases that were selected to move into the bellwether case-specific discovery phase. After the conclusion of case-specific discovery, Presiding Judge David Herndon will select four of the 16 cases to proceed to trial on August 11, 2014, November 3, 2014, January 5, 2015, and February 16, 2015. Judge Herndon’s selection of the four trial cases will occur on or before November 22, 2013.
Bellwether case selection is a judicial procedure where a select group of cases are presented for determining core issues, such as liability and damages, for the remaining cases. The outcome of the bellwether trials typically assists in the resolution of all cases within multi-district litigation. They also assist in expediting the trial process. In the case of Pradaxa litigation Judge Herndon promised an expedited process due to the age of the plaintiffs, among other factors.
“The patient whose case was selected for the bellwether selection suffered a near fatal episode of gastrointestinal bleeding just two weeks after her initial dose of Pradaxa,” said Patrick Dennis, the Doyle Raizner partner who manages the firm’s pharmaceutical docket.
Pradaxa litigation was consolidated into a MDL in August 2012 in the Southern District of Illinois, a federal court. [Docket No. 3:13-cv-50028-DRH-SCW] The court will handle claims that the blood thinner, Pradaxa, has serious and often deadly adverse side effects, including an increased risk of gastrointestinal and other bleeds, which were not properly communicated by Boehringer Ingelheim to healthcare professionals or patients. The drug is often prescribed to elderly patients to reduce the risk of stroke in people with atrial fibrillation. Compounding, a possible internal bleeding risk is the lack of an antidote to stop Pradaxa’s internal bleeding side effect. No antidote exists because Pradaxa was rushed to market before Boehringer Ingelheim took efforts to develop an antidote to protect patients taking this drug. As a result, many takers of Pradaxa have suffered from hemorrhages and deaths. The large number of complaints and impending personal injury cases against Pradaxa moved it to the top of 2011’s most dangerous drug report issued by the Institute for Safe Medication Practices, January 12, 2012.
To learn more about the firm and their part in Pradaxa litigation, please visit http://www.PradaxaLitigation.com.
About Doyle Raizner LLP:
Doyle Raizner LLP is a national personal injury litigation firm with main offices in Houston, Texas and Phoenix, Arizona. The firm's attorneys specialize in helping victims’ secure fair compensation for injuries or the death of a loved one.
Jeff Raizner, Doyle Raizner LLP, http://www.doyleraizner.com/, (713) 571-1146, [email protected]
Share this article